Transcription of ANNUAL REPORT 2017 - viforpharma.com
{{id}} {{{paragraph}}}
ANNUAL . REPORT . 2017 . ANNUAL REPORT 2017 . AT A GLANCE. Guidance raised at half-year, continued good performance in H2. led to strong full-year results Net sales CHF 1, million, up on a constant currency basis EBITDA CHF million, up excluding Veltassa launch costs Cash net of debt of CHF million Transformation into a pure-play pharmaceutical company successfully completed Separation of Galenica Sant via initial public offering (IPO). Etienne Jornod re-elected as Executive Chairman with remuneration exclusively in shares blocked until 2020. Change of name from Galenica Group to Vifor Pharma Group New Executive Committee appointed Operational headquarters transferred from Bern to Zurich Reported net sales growth of Ferinject + for full year 2017 .
Vifor Pharma Ltd. Annual Report 2017 7 172 We are extremely proud of our employees’ outstanding achievements in 2017 and we are grateful for their efforts to ensure a strong
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}